Researchers from Harvard University and Karolinska Institute in Stockholm converted cardiac stem cells into blood vessels using synthetic messenger RNA in the damaged hearts of mice. The study in Nature Biotechnology shows the potential of using modified RNA that codes for the protein VEGF-A in the development of new heart tissue. AstraZeneca and Moderna Therapeutics are working to develop the approach for use in patients.

Related Summaries